Part of Your
VIVITROL® (naltrexone for extended-release injectable suspension) is a non-addictive, once-monthly treatment proven to prevent relapse in opioid-dependent patients when used with counseling following opioid detoxification.1,2
Before starting VIVITROL, you must be opioid-free for a minimum of 7 to 14 days to avoid sudden opioid withdrawal.1
VIVITROL must be injected by a healthcare provider.
WHAT IS VIVITROL?
VIVITROL is a prescription injectable medicine used to:
- Prevent relapse to opioid dependence after opioid detox. You must stop taking opioids or other opioid-containing medications before starting VIVITROL.
- Treat alcohol dependence. You should stop drinking before starting VIVITROL.
To be effective, VIVITROL must be used with other alcohol or drug recovery programs such as counseling.
It is not known if VIVITROL is safe and effective in children.
You should not take VIVITROL if you:
- Are using or have physical dependence on opioid-containing medicines or opioid street drugs.
- Have opioid withdrawal symptoms. Opioid withdrawal symptoms may happen when you have been taking opioid-containing medicines or opioid street drugs regularly and then stop.
- Are allergic to naltrexone or any of the ingredients in VIVITROL or the liquid used to mix VIVITROL.
VIVITROL is not right for everyone. There are significant risks from VIVITROL treatment, including risk of opioid overdose, severe reaction at the injection site and sudden opioid withdrawal.
See Important Safety Information in the Brief Summary of Important Facts about VIVITROL below. Discuss all benefits and risks with a healthcare provider. See Prescribing Information and Medication Guide.
Find A Treatment Provider
This tool can help you find a healthcare provider in your area who can answer your questions about VIVITROL.
LEARN ABOUT THE VIVITROL® CO-PAY SAVINGS PROGRAM
Learn how the VIVITROL® Co-pay Savings Program may assist eligible* patients with out-of-pocket expenses for their VIVITROL prescriptions.LEARN MORE
- VIVITROL [prescribing information]. Waltham, MA: Alkermes, Inc; rev September 2019.
- Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377(9776):1506-1513.
*Terms and ConditionsEligibility for Alkermes-Sponsored Co-pay Savings. This offer is only available to patients 18 years or older, with a prescription consistent with the Prescribing Information and the patient is not enrolled in, or covered by, any local, state, federal or other government program that pays for any portion of medication costs, including but not limited to Medicare, including Medicare Part D or Medicare Advantage plans; Medicaid, including Medicaid Managed Care and Alternative Benefit Plans under the Affordable Care Act; Medigap; VA; DOD; TRICARE; or a residential correctional program.